TT 2016 Program Schedule 021816

Bladder Cancer Think Tank 2016 Program Schedule August 11-13, 2016 Denver, CO Collaborating to Move Research Forward Thu...

0 downloads 30 Views 308KB Size
Bladder Cancer Think Tank 2016 Program Schedule August 11-13, 2016 Denver, CO Collaborating to Move Research Forward Thursday, August 11 10:00 – 1:00

Patient Advocacy Session (for patient advocates only)

3:00 – 4:00


4:00 – 5:00

Opening Remarks, Introductions, BCAN Presentation Diane Z. Quale, Bladder Cancer Advocacy Network Jonathan Rosenberg, MD, Memorial Sloan Kettering Cancer Center, Chair, Think Tank 2016 Matt Nielsen, MD, University of North Carolina, Chapel Hill, Co-Chair, Think Tank 2016

5:00 – 6:00

Keynote Address and Q&A “Palliative Care” Jennifer Temel, MD, Massachusetts General Hospital

6:00 – 9:00

Reception, Dinner and Advocate Remarks

Friday, August 12 7:00 – 8:00


8:00 – 9:45

PANEL: Financial Toxicity in Cancer Care - How the cost of progress is affecting patients Yu-Ning Wong, MD, MCSE, Fox Chase Cancer Center and Matt Nielsen, MD, MS, University of North Carolina, Panel Co-Chairs Yousuf Zafar, MD, MHS, Duke Cancer Institute Jonas De Souza, MD, U. Chicago Lowell Schnipper, MD, Beth Israel Deaconess Medical Center

9:45 – 10:15

2014 JAMES FAMILY FOUNDATION AND PARTNER FUND MANAGEMENT BLADDER CANCER RESEARCH INNOVATION AWARD William Kim, MD, Associate Professor of Medicine, Urology, and Genetics, University of North Carolina at Chapel Hill and UNC Lineberger Comprehensive Cancer Center “Immune Characterization of High-Grade Bladder Cancer.”

10:15 – 10:30

Travel Fellow Presentation 1|2016 Think Tank Schedule

10:15 – 10:45



Breakout Sessions | Please see Appendix A.

12:15 – 1:30


1:30– 3:30

PANEL: Bladder Preservation Updates, Controversies, and Future Perspectives James McKiernan, MD, Columbia New York Presbyterian and Jason Efstathiou, MD, DPhil, Mass. General Hospital, Co-Chairs James McKiernan, MD, Columbia New York Presbyterian Jason Efstathiou, MD, DPhil, Mass. General Hospital Angela Smith, MD, University of North Carolina, Chapel Hill Kimberly Mak, MD, M.P.H., Brigham and Woman’s Hospital Anne Kiltie, BM, BCh, MA, DM, University of Oxford William Shipley, MD, Massachusetts General Hospital

3:30– 4:00

Travel Fellow Presentations


Happy Hour Activity

Saturday, August 13 7:00 – 8:00


8:00 – 9:00

BCAN 2014 Young Investigator Presentations BCAN YOUNG INVESTIGATOR AWARD Sunny Guin, PhD, Postdoctoral Fellow, University of Colorado at Denver “The Role, Relationship and Therapeutic Potential of HAS2 and AGL in Bladder Cancer” THE JPB FOUNDATION YOUNG INVESTIGATOR AWARD Ryoichi Saito, MD, PhD, Research Associate, University of North Carolina at Chapel Hill “Consequences of ARID1A Inactivation in Bladder Cancer” THE JPB FOUNDATION YOUNG INVESTIGATOR AWARD Dmitriy Zamarin, MD, PhD, Hematology/Oncology Fellow, Memorial Sloan-Kettering Cancer Center “Defining Immunotherapy Targets in Bladder Cancer Microenvironment Using Oncolytic Viruses”

9:00 – 9:30


9:30– 11:15

Breakout Sessions and Working Groups | Please see Appendix B

11:15 – 12:30


2|2016 Think Tank Schedule

12:30 – 12:45

Travel Fellow Presentation

12:45 – 2:45

PANEL: Translational Impact of Stem/Progenitor Cells in Bladder Cancer Keith Chan, PhD, Baylor College of Medicine and David DeGraff, PhD, Penn State University College of Medicine, Panel Co-Chairs Cathy Mendelsohn, Ph.D., Columbia University Phil Beachy, PhD, Stanford University Dan Theodorescu, MD, PhD, University of Colorado Keith Chan, Ph.D., Baylor University Joseph Liao, M.D., Stanford University

2:45 – 3:00

Closing Remarks

3|2016 Think Tank Schedule

APPENDIX A | FRIDAY MORNING BREAKOUT SESSION DESCRIPTIONS What’s Next in Immunotherapy for Bladder Cancer? Betsy Plimack and Dan Petrylak, Co-Chairs In-depth discussion of emerging challenges in the field of immunotherapeutics for bladder cancer, including resistant phenotypes, novel immune combinations and targets, as well as chemotherapy / immunotherapy combinations and sequences. Barriers to Providing Palliative Care in Bladder Cancer: Mary Dunn and Tracy Downs, Co-Chairs Palliative care is a multidisciplinary approach that improves the quality of life of patients and families across the spectrum of an illness or disease. Discussion will address fact vs fiction, communication techniques, and overcoming barriers to providing palliative care in bladder cancer. Clinical and Translational Opportunities in Urothelial Cancer of the Upper Urinary Tract: Surena Matin and Vitaly Margulis , Co-Chairs Updates on trials in development and ongoing clinical trials for patients with upper tract urothelial cancer. Patient Centered Outcomes: John Gore and Seth Strope, Co-Chairs Discussion on the role of patient-centered outcomes research in bladder cancer research and care, including patient reported outcome tools, research prioritization important to patients, and tailoring the medical record to patients. Selecting the ‘Right' Urinary Diversion: Navigating the Choices: Sia Daneshmand and Scott Gilbert , Co-Chairs Short presentations and in-depth discussion on orthotopic diversion, continent cutaneous diversion and health related quality of life for patients with urinary diversions. Tough Cases 1 - Variant histology in urothelial cancer: a time for inclusion in clinical trials? : Donna Hansel and Arlene Siefker-Radtke, Co-Chairs Discussion of the clinical presentation, underlying biology, and current treatment outcomes focusing on 3 rare variants: micropapillary, plasmacytoid, and urachal carcinoma. Financial Toxicity Follow-Up: Ning Wong and Matt Nielsen, Co-Chairs Continuing the panel discussion, patients and providers will discuss issues the value of care and financial toxicity and areas of future research. BCGC-UC GENOME: Bringing Precision Medicine to Bladder Cancer, Matt Milowsky and Gopa Iyer, CoChairs Discuss best practices for the interpretation of genomics data utilizing the Bladder Cancer Genomics Consortium (BCGC) Urothelial Cancer – GENOmic analysis to iMprove patient outcomes and rEsearch (UC-GENOME) project. Review potential therapeutic targets and clinical trials for actionable alterations in bladder cancer.

4|2016 Think Tank Schedule

APPENDIX B | SATURDAY MORNING BREAKOUT SESSION DESCRIPTIONS Novel Imaging in Bladder Cancer: Closing the Gap between Clinical and Pathologic Staging: Arjun Balar and Piyush Argawal, Co-Chairs Explore new techniques that may potentially enhance staging of localized bladder tumors and metastatic urothelial cancer. Do these techniques improve upon standard of care or are they expensive technologies with little ability to impact care? Improving Outcomes - Nutrition & Bladder Cancer: Steve Riggs and Jill Hamilton-Reeves, Co-Chairs Understand the clinical outcome benefits associated with the use of nutrition regimens in bladder cancer patients. Explore why specialized immunonutrition benefits major surgery patients in a way that standard nutrition cannot. Discuss the clinical impact of malnutrition in radical cystectomy. Experts present data and cases through the lenses of translational science, clinical research, and practice. Tough Cases 2: Management of localized unresectable disease: Ann Kiltie and Matt Galsky, Co-Chairs Experts in the field of urology, radiation oncology and medical oncology discuss the issues involved in treating localized unresectable bladder disease. This difficult scenario receives scant attention in national and international guidelines and can be challenging to manage. Optimizing mouse models for bladder cancer research: Cory Abate-Shen and William Kim, Co-Chairs The generation of informative mouse models has the potential to improve our understanding of bladder cancer progression, as well as impact its diagnosis and treatment. However, relatively few in vivo animal models of bladder cancer have been described and particularly few that represent invasive cancer phenotypes. This session will discuss the challenges and opportunities for improving the landscape of models of bladder cancer. Bladder Preservation Follow Up - Future Perspectives: Jim McKiernan & Jason Efstathiou, Co-Chairs Addressing areas of controversy including topics such as cystectomy vs bladder-sparing therapy, the role of neoadjuvant chemotherapy, surgical considerations such as feasibility of constructing a neobladder at the time of salvage cystectomy, response of CIS to chemoradiation, and institutional project updates. Working Group: Upper Tract Disease. Surena Matin and Vitaly Margulis, Co-Chairs Upper tract urothelial carcinoma (UTUC) is an uncommon disease with little evidence-based data to guide clinical decision making. This ongoing working group continues to build collaborative multi-institutional projects to improve clinical risk stratification and develop new treatment paradigms for UTUC. New members welcome. Working Group: Survivorship. Tracy Downs and Heather Goltz, Co-Chairs Develop programs that improve quality of life for bladder cancer survivors, caregivers, and family through education, research and advocacy. New members welcome. Working Group: Patient Centered Outcomes. John Gore and Seth Strope, Co-Chairs Discuss research prioritization important to patients and patient advocates. Presenting the results of the PCORI funded patient centered research prioritization effort performed through BCAN. Further engagement from patients, advocates, and clinicians will be enlisted to help drive this research prioritization effort forward. New members welcome. 5|2016 Think Tank Schedule